Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,907 shares of the biopharmaceutical company’s stock after selling 187 shares during the quarter. Gilman Hill Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $4,310,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $697,296,000. Capital International Investors boosted its position in shares of Regeneron Pharmaceuticals by 37.3% during the 2nd quarter. Capital International Investors now owns 2,956,615 shares of the biopharmaceutical company’s stock worth $2,124,326,000 after acquiring an additional 803,143 shares in the last quarter. FMR LLC boosted its position in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after acquiring an additional 669,517 shares in the last quarter. Moneta Group Investment Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 57,848.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company’s stock worth $420,184,000 after acquiring an additional 581,379 shares in the last quarter. Finally, Virginia Retirement Systems ET AL acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $83,318,000. 84.15% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $935.00 to $937.00 and gave the company a “buy” rating in a report on Tuesday, November 28th. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, January 5th. Royal Bank of Canada boosted their target price on Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. Finally, BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $959.09.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $4.55 on Monday, hitting $959.92. 360,151 shares of the company’s stock were exchanged, compared to its average volume of 518,782. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm’s 50-day moving average price is $952.30 and its two-hundred day moving average price is $873.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The firm has a market cap of $105.36 billion, a price-to-earnings ratio of 27.62, a P/E/G ratio of 2.78 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $10.96 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.5 EPS for the current year.

Insider Buying and Selling

In related news, Director Michael S. Brown sold 2,049 shares of the company’s stock in a transaction that occurred on Wednesday, December 27th. The stock was sold at an average price of $898.00, for a total value of $1,840,002.00. Following the sale, the director now owns 1,247 shares in the company, valued at approximately $1,119,806. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael S. Brown sold 2,049 shares of the stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $898.00, for a total value of $1,840,002.00. Following the sale, the director now owns 1,247 shares in the company, valued at approximately $1,119,806. The disclosure for this sale can be found here. Insiders have sold a total of 19,906 shares of company stock worth $18,479,805 in the last quarter. Company insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.